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Background: Toxoplasmosis is caused by infection with a ubiquitous intracellular protozoan 
parasite, Toxoplasma gondii. With the advent of the HIV pandemic in Nigeria, toxoplasmic 
encephalitis has become one of the more frequent opportunistic infections and the most 
  commonly implicated cause of focal brain lesions complicating the course of AIDS.
Objectives: This study was conducted to compare the pattern of seroprevalence of T. gondii 
(Toxo-IgG) antibodies among HIV-infected persons presenting with neurological complications 
and those without.
Materials and methods: Plasma specimens collected from 380 subjects were tested for 
  Toxo-IgG antibodies by enzyme immunoassay technique and CD4 estimation by flow cytometry. 
Close-ended questionnaires were applied to all respondents to collect relevant data, with   ethical 
approval from the hospital ethical committee. Plasma was obtained from two study groups 
comprising 300 HIV-positive respondents without neurological presentations, and 80 HIV-
positive respondents with neurological complications.
Results: Seroprevalence of Toxo-IgG antibodies was 58% in the HIV-positive study group 
without neurological complications (of these, 79.2% were males and 38.5% were females) 
and 40% in the study group with neurological complications (46.2% of these were males 
and 28.6% were females). The overall seroprevalence of Toxo-IgG antibodies among the 
HIV-positive respondents (with and without neurological complications) was 54.2% (206 of 
380). Seroprevalence of Toxo-IgG antibodies was lowest among the educated subjects (19% 
of the respondents with tertiary education) and among females in both study groups. A higher   
proportion of the subjects with neurological complications had CD4 cell count ,100 cells/µL 
compared with respondents without neurological defects (39% vs 22.7%; P = 0.000), but the 
seroprevalence of Toxo-IgG antibodies was higher in subjects without neurological complica-
tions (45% vs 31.3%; P = 0.000).
Conclusion: Toxoplasmosis, though an important opportunistic infection in our environment, 
may not account for the majority of neurological complications observed in patients with HIV 
infection in our center.
Keywords: Toxoplasma gondii antibody (Toxo-IgG), seroprevalence, neurological 
complication
Introduction
Toxoplasmosis is caused by infection with a ubiquitous intracellular protozoan, 
Toxoplasma gondii.1 Reproduction is both sexual and asexual. Sexual reproduction 
occurs in definitive hosts mostly involving the cat family, and occasionally mice or rats.1 
Asexual reproduction occurs in a wide range of animals, which includes man as inter-
mediate host.1,2 The onset of cellular immunity against T. gondii is mediated by T-cells, HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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macrophages, and activities of type-1 cytokines (interleukin-1 
and interferon gamma). This is accompanied by the transfor-
mation of the parasite into tissue cysts resulting in chronic 
infection.3 Humoral immune response is initiated by the pro-
duction of specific Toxoplasma gondii antibodies toxoplasma 
antibodies (IgM and IgG).3 IgM antibody response occurs as 
an early event, and disappears within a few weeks or months, 
thus its presence in plasma indicates recent infection.3,4 IgG 
antibody production peaks within 1 to 2 months after infection 
but remains elevated for life.4 Several methods for diagnosis 
of toxoplasmosis exist and include: isolation in vivo (mice) 
and in vitro (tissue culture); detection of T. gondii by DNA 
polymerase chain reaction (PCR) from body fluids; computed 
tomography (CT) scan and magnetic resonance imaging.5–8 
Serologic testing remains the routine method of diagnosis,4 
especially in resource-poor countries where it is the most 
available and affordable means of detecting the presence of 
Toxoplasma gondii antibodies (Toxo-IgG and IgM antibodies) 
and IgM antibodies. It has been documented that more than 
97% of HIV-infected individuals with toxoplasma encephali-
tis will test positive for Toxo-IgG antibodies.4 Therefore, the 
absence of Toxo-IgG antibodies in plasma strongly argues 
against the diagnosis of toxoplasmosis.4 Serological studies 
in many groups have shown that about 20% of people would 
have acquired the infection by the age of 20, and up to 50% 
by the age of 70.4 Primary infection in a normal, immuno-
competent individual is usually subclinical or associated with 
self-limiting nonspecific symptoms like fever and malaise.9 
However, in immunocompromised patients such as HIV-
infected persons, reactivation of latent disease can cause 
life threatening encephalitis;2 offspring of infected mothers 
may present with mental retardation, blindness, epilepsy, 
or stillbirth.10 Toxoplasmic encephalitis has become one 
of the most frequent opportunistic infections complicating 
HIV infection, and the most common cause of focal brain 
lesion, coma, and death.
In Nigeria, management of patients presenting neurologi-
cal symptoms poses a major clinical challenge because of the 
numerous possible differential diagnoses, which   commonly 
include central nervous system lymphoma, fungal abscess, 
mycobacterial infection, cytomegaloviral and other direct 
viral infections, and Kaposi’s sarcoma among others for which 
diagnostic procedures may be cumbersome and expensive 
to undertake.9 This study therefore was designed to com-
pare the pattern of seroprevalence of Toxo-IgG antibodies 
in HIV-infected persons without neurological deficits, and 
HIV-infected persons manifesting any form of neurological 
complications including motor weaknesses and speech 
disturbances, seizures, cranial nerve abnormalities, sensory 
  disturbances, cerebellar dysfunction, meningismus,   movement 
disorders, and neuropsychiatric manifestations, and to 
determine the proportion of these patients whose neurological 
deficits may be remotely attributable to T. gondii infection
Materials and methods
Study location
This study was carried out at the Lagos University   Teaching 
Hospital, Lagos State in the south-west region of   Nigeria. 
Ethical approval for the study was obtained from the hospital 
ethical committee. Participants were recruited from the 
out-patient clinic of the hospital, which had over 6000 
registered HIV-positive patients from different socioethnic 
backgrounds.
Study population
Three hundred and eighty subjects who screened and confirmed 
positive for HIV-1 or -2 were recruited by random sampling 
technique at the point of registration. The 380 HIV-positive 
respondents were separated into 2 study groups based on the 
presence of clinical evidence of neurological symptoms. Of 
the participants, 300 were without any obvious neurological 
symptoms while 80 of the HIV-positive participants presented 
with symptoms which included: neck stiffness, photophobia, 
tremors, irrational talk, paraesthesia, insomnia, and persistent 
headache, as isolated disorders or in any combination.
Patients with previous history of anti-retroviral drug 
therapy, cerebrovascular accidents, septrin prophylaxis, 
pyrimethamine, and chemotherapy were excluded from the 
study.
Sample collection and processing
Two venous blood samples of 4.5 mL each were drawn from 
each subject into Na-EDTA specimen tubes. Plasma was 
obtained by centrifugation at 3000 rpm for 5 minutes, and 
stored at -20°C, prior to Toxo-IgG assay. All collected plasma 
were analyzed using ELISA by Immuno-comb Toxo-IgG kit 
manufactured by Orgenics Ltd, Yavne, Israel, with a sensitivity 
of 97.2% and specificity of 93.75%. CD4 estimation was 
carried out with a flow cytometer (Partec-model SL3).
Interpretation of results
Positive control must produce 2 spots on the card tooth to be 
valid; negative control must produce only an upper control 
spot to be valid. A lower spot with an intensity higher than 
or equal to that of positive indicates the presence of IgG 
antibody to Toxoplasma gondii.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Statistical analysis
The data were analyzed using statistical software SPSS 
version 11 (SPSS Inc, Chicago, IL). The data on qualitative 
variables were indicated by frequency and percentages, and 
quantitative variables by range and mean. Associations were 
verified by Chi-square with level of significance placed at 
P , 0.05 (5%).
Results
Demographic characteristics  
(Tables 1 and 2)
Mean ages of participants (HIV-positive subjects with 
neurological symptoms and HIV-positive subjects   without 
neurological symptoms) were 39.5 ± 4.8 years and 
38.4 ± 7.2 years respectively. A higher proportion of the 
subjects (140 of 380, 36.7%) were between the age range 
of 37 to 46 years.
Of the respondents, 196 were males (51.6%) and 184 
were females (48.4%). Most respondents (264 of 380, 
69.5%) were married. Only 31.6% of HIV-positive subjects 
had a tertiary education (120 of 380). The neurological 
symptoms manifested by these HIV-positive respondents 
were: headache (20%), neck stiffness (14%), photophobia 
(6.3%), paraesthesia (6.3%), tremor (20%), irrational talk 
(20%), and insomnia (14%). Of these, tremor, headache, 
and irrational talk constituted the majority of the clinical 
presentations (60%).
Seroprevalence of Toxo-Igg antibody 
among respondents (Tables 2 and 3)
Seroprevalence of Toxo-IgG antibody was 40% among the 
HIV-positive study group with neurological symptoms and 
58% among the HIV-positive study group without neurologi-
cal symptoms (P = 0.00).
There was a higher seroprevalence of Toxo-IgG anti-
bodies among the age range of 37–46 years (102 of 140) 
representing 72.9% of the total in that age group. This was 
statistically significant at P = 0.00.
Toxo-Igg antibody and associated  
factors in HIV-infected respondents  
(Tables 3 and 4)
Of the 380 HIV-positive subjects, 206 were seropositive 
for Toxo-IgG antibodies (54.2%). Toxo-IgG antibody 
was more prevalent among the male subjects (70.4%). 
However this association was only statistically significant 
among the study group without neurological symptoms 
(P = 0.00).
CD4 count of all HIV-positive respondents ranged 
between 7 and 772 cells/µL, with a median count of 
320 cells/µL. Of the HIV-positive study group without 
  neurological complications who had CD4 count below 
100 cells/µL, 79.4% were seropositive for Toxo-IgG antibody 
(statistically significant, P = 0.00), compared with 32.2% in 
subjects with neurological complications.
The association between Toxo-IgG antibody and HIV 
infection was more significant among the HIV-positive 
study group without neurological symptoms (P = 0.00). 
Seroprevalance of Toxo-IgG antibody in the HIV-
positive study group with neurological deficit was only 
Table 1 Demographic characteristic of subjects
Characteristics HIV patients  
with neurological  
symptoms
HIV patients  
without neurological 
symptoms
Total number  
of subjects
80 300
Age (years) 39.6 ± 4.8 38.6 ± 7.2
Sex of subjects N (%) N (%)
Male 52 (26.5) 144 (74.5)
Female 28 (15.2) 156 (84.8)
Educational  
background
N (%) N (%)
Primary 16 (23.9) 51 (76.1)
Secondary 40 (20.7) 153 (79.3)
Tertiary 24 (20) 96 (80)
Table  2  Seroprevalence  of  anti-Toxoplasma  gondii  (Toxo-Igg), 
sex and age of all respondents (with and without neurological 
symptoms)
Age Toxo-IgG  
+ve N (%)
Toxo-IgG  
−ve N (%)
Total Chi2 P-value
Subjects with neurological complication
  16–26 4 (25) 12 (75) 16 5.28 0.15
  27–36 8 (40) 12 (60) 20
  37–46 12 (60) 8 (40) 20
 . 46 8 (33) 16 (67) 24
Sex
  Male 114 (79) 30 (21) 144 50.93 0.00
  Female 60 (39) 96 (61) 156
Subjects without neurological complication
Age
  16–26 15 (50) 15 (50) 30 25.99 0.00
  27–36 51 (50) 51 (50) 102
  37–46 90 (75) 30 (25) 120
 . 46 18 (38) 30 (62) 48
Sex
  Male 24 (46) 28 (54) 52 54.07 0.02
  Female 8 (29) 20 (71) 28HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
104
Osunkalu et al
demonstrable in 40% of the total respondents (32 of 80), 
compared with 58% in subjects without neurological 
complications.
Discussion
In this study, the data showed a Toxo-IgG antibody 
seroprevalence rate of 54.2% in HIV-infected persons. 
Earlier serological studies in many groups showed that the 
prevalence varied depending on the geographical location, 
between 15% and 68%. A recent US survey estimated a 
prevalence rate of 15% in the general population11 and 
40% in people with HIV .11 Nissapatorn et al evaluated 
the prevalence in 505 HIV-positive patients admitted to a 
hospital in Malaysia and reported a prevalence of 44.8%.12 
Wanachiwanawin et al estimated a prevalence rate of 53.7% 
in the HIV-infected population in Thailand.13 Meisheri et al 
in India reported a prevalence rate of 30.9% and 67.8% 
in the immunocompetent group and HIV-infected persons 
respectively.14 Galva Ramirez et al estimated a prevalence 
rate of 50% in the HIV-infected population in Mexico.15 In 
Africa, Lindstrom et al evaluated 130 HIV-positive patients 
in Uganda and estimated a prevalence rate of 54%.16 The 
prevalence rate in this study equates well to that seen in the 
African study in Uganda, and that seen in Mexico.
The slight variations in prevalence rates obtained in 
this study compared with other earlier studies could be 
attributed to differences in geographical location.   Infection 
is more common in warm climates, and at lower altitudes 
than in cold climates and mountainous regions.12   However, 
public enlightenment/health education, and high Human 
Development Index (HDI) standards could also be responsible 
for reduced infection.
The overall seroprevalence was highest (72.9%), in the 
37 to 46 year age group, which is in agreement with an 
earlier report by Meisheri et al, which showed the highest 
prevalence within third and fourth decades of life.14 However, 
Nissapatorn et al reported the highest prevalence rate 
within the second and third decades of life.12 The increasing 
prevalence rate with increasing age could be explained by 
increased risk of exposure to infection with increasing age. 
There is no statistical significant difference in age distribution 
between HIV-infected patients with neurological symptoms 
and those without.
Most Toxo-IgG antibody seropositive cases were males. 
The sex predilection could be attributed to the higher risk of 
consumption of meat (more likely to be contaminated) among 
Nigerian males.16 There was an association between a CD4 
count ,100 cells/µL and Toxo-IgG antibody seropositivity 
in HIV-positive subjects without neurological symptoms: 
79.4% of the HIV-positive study group without neurological 
symptoms who had a CD4 count ,100 cells/µL were   
seropositive for Toxo-IgG antibodies (P = 0.00). But this 
association was not observed in subjects with neurological 
symptoms (32.2%; P = 0.26). Studies by Eliaszewicz et al 
in France, which included 172 HIV-infected subjects with 
diagnosed cerebral toxoplasmosis, showed that 79% of 
these patients had CD4 count ,150 cells/µL.17 This result 
is contrary to findings in this study, which may further 
confirm the earlier position that neurological complica-
tion among HIV-positive subjects may be significantly 
unrelated to   toxoplasmic infections. Johnson and Sayles 
studied resistance to T. gondii infection in mice lacking CD4 
expression, and concluded that CD4-deficient mice exhibited 
impaired resistance to a challenge infection with virulent 
tachyzoites;18 therefore HIV infection increases susceptibility 
to T. gondii infection (not necessarily with toxoplasmic 
encephalitis). Thus CD4 serves as a reliable indicator for 
possible toxoplasmosis, and also contributes significantly to 
protection against chronic T.   gondii infections via their role as 
helper cells for production of isotype-switched antibodies.18 
However,   findings from this study showed that only 40%   
Table 3 Association between anti-Toxoplasma gondii (Toxo-Igg) antibody and symptoms of neurological disorders in the HIV-positive 
subjects
Toxo-IgG  
antibody status
Symptomatic  
subjects: N (%)
Asymptomatic  
subjects: N (%)
Total Chi2 P-value
Positive 32 (40) 174 (58) 206 8.24 0.00
negative 48 (60) 126 (42) 174
Table 4 Association between CD4 count and prevalence of anti-
Toxoplasma gondii (Toxo-Igg) antibodies among subjects
CD4  
(cells/μL)
Toxo-IgG  
+ve N (%)
Toxo-IgG  
–ve N (%)
Total Chi2 P-value
Subjects with neurological complications
#100 10 (32.2) 21 (67.1) 31 5.28 0.15
$100 22 (44.1) 27 (55.1) 49
Respondent without neurological complications
#100 54 (79.4) 14 (20.6) 68 16.55 0.00
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of all respondents with neurological complications were 
seropositive for Toxo-IgG antibody compared with 58% of 
HIV-positive subjects without neurological complications. 
This implies that 60% of the subjects with neurological 
complications actually have other possible etiological   factors; 
therefore the occurrence of neurological complications 
among participants in this study is not associated with higher 
incidence of Toxo-IgG antibody seropositivity compared 
with HIV-positive subjects without neurological deficit, thus 
implying that neurological complications observed in this 
study group might be from direct invasion of the neural cells 
by the HIV virus, or other common differentials.
Conclusion
In this study, the seroprevalence rate of Toxo-IgG antibody 
in HIV-infected patients, with and without neurological 
  deficits, was evaluated. It may be concluded that though   
T. gondii infection is highly prevalent in our environment, 
it may not be responsible for the majority of cases of 
  neurological disorders observed in our HIV-positive patients. 
However, extensive study in this area, using more accurate 
methodology including CT scan and PCR techniques, may 
be needed to establish the exact incidence of toxoplasmic 
encephalitis in these patients and evaluate differentials.
Disclosure
The authors declare no conflicts of interest.
References
1.  Wilson M, McAuley JB. Toxoplasma Manual of Clinical Microbiol-
ogy, 7th ed, Murray P. editor, Washington DC: ASM Press; 1999;35: 
1374–1382.
2.  Montoya JG, Hesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425): 
1965–1976.
3.  Subauste CS, Remington JS. Immunity to Toxoplasma gondii. Curr Opin 
Immunol. 1993;5(4):532–537.
4.  Montoya JG, Remington JS. Toxoplasma gondii. In: Mandell GL, 
Beneth JE, Dohin R, editors. Principles and Practice of Infectious Dis-
eases. Philadelphia: Churchill Livingstone; 2000:2858–2888.
  5.  Bretagne S, Costa JM, Fluery-Feith J, Poron F, Dubreuil-Lemaire ML, 
Vidaud M. Quantitative competitive PCR with broncho-alveolar lavage 
fluid for diagnosis of toxoplasmosis in AIDS patients. J Clin Microbiol. 
1995;33(6):1662–1664.
  6.  Danise A, Cinque P, Vergani S, et al. Use of polymerase chain reaction 
assays of aqueous humor in the differential diagnosis of retinitis in 
patients infected with human immunodeficiency virus. Clin Infect Dis. 
1997;24(6):1100–1106.
  7.  Levy RM, Rosenbloom S, Perrett LV . Neurologic findings in AIDS;   
a review of 2000 cases. AJR AM J Roetgenol. 1986;147(5):977–983.
  8.  Levy RM, Mills CM, Posin JP, Moore SO, Rosenblum ML, Bredesn DE. 
The efficacy and clinical impact of brain imaging in neurological 
symptomatic AIDS patients a prospective CT/MRI study. J Acquir 
Immune Defic Syndr. 1990;3(5):461–471.
  9.  Navia BA, Petito CK, Gold JW, Cho ES, Jordan BD, Price RW. Cerebral 
toxoplasmosis complicating the acquired immune deficiency syndrome: 
clinical and neuropathological findings in 27 patients. Ann Neurol. 1986; 
19(3):224–238.
  10.  Foulon W. Treatment of toxoplasmosis during pregnancy: a multicenter 
study of impact on fetal transmission and children’s sequelae at age 
1 year. Am J Obstet Gynecol. 1999;180:410–415.
  11.  Lones JL, Kruzson D. Toxoplasma gondii infection in US 1999–2000. 
Emerg Infect Dis. 2003;9:11.
  12.  Nissapatorn V , Lee CKC, Cho SM, et al. Toxoplasmosis in HIV/AIDS 
patients in Malaysia. Southeast Asian J Trop Med Public Health. 2003; 
34(2):80–85.
  13.  Wanachiwanawin D, Sutthent T, Chokephaibultkit K, Mahakittikun V , 
Ongrotchnakun J, Monkong N. Toxoplasma gondii antibodies in HIV 
and non HIV infected Thai pregnant women. Asian Pac J Allergy 
Immunol. 2001;19:291–293.
  14.  Meisheri YV , Mehta S, Patel U. A prospective study of seroprevalence 
of Toxoplasmosis in general population, and in HIV/AIDS patients in 
Bombay, India. J Postgrad Med. 1997;43:93–97.
  15.  Galva Ramirez ML, Valdez Alvarodo V , Vargas Gutierrez G, Jimenez 
Gonzalez O, Garcia Cosio C, Vielma Sandoval M. Prevalence of IgG 
and Igm anti-Toxoplasma antibodies in patients with HIV and AIDS. 
Rev Soc Bras Med Trop. 1997;30:465–467.
  16.  Lindstrom I, Kaddu-Mulindwa DH, Kironde F, Lindh J. Prevalence of 
latent and reactivated Toxoplasma gondii parasites in HIV-patient from 
Uganda. Acta Trop. 2006;100(3):218–222.
  17.  Eliaszewicz M, Lecomte I, De Sa M. Relation between decreasing 
series CD4 lymphocyte count and outcome of toxoplasmosis in AIDS 
patients: a basis for primary prophylaxis. Int Conf AIDS. 1990;6(242): 
20–23.
  18.  Johnson LL, Sayles PC. Deficient humoral responses underlie 
susceptibility to Toxoplasma gondii in CD4-deficient mice. Infect 
Immun. 2002;70(1):185–219.